Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 8/2021

01-08-2021 | Systemic Therapy | Special Section: HCC Treatment

Frontiers of therapy for hepatocellular carcinoma

Authors: Michael Heller, Neehar D. Parikh, Nicholas Fidelman, Dawn Owen

Published in: Abdominal Radiology | Issue 8/2021

Login to get access

Abstract

The incidence of hepatocellular carcinoma continues to increase worldwide. Fortunately, there have been notable recent advances in locoregional and systemic therapy. In this current review, we will highlight these new developments and future directions of hepatocellular carcinoma treatment and address the importance of a multidisciplinary approach to treatment.
Literature
1.
Yang M, Parikh ND, Liu H, Wu E, Rao H, Feng B, et al. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. Sci Rep. 2020;10(1):20922.PubMedPubMedCentralCrossRef
2.
Reinders MTM, van Meer S, Burgmans MC, de Jong KP, Klumpen HJ, de Man RA, et al. Trends in incidence, diagnosis, treatment and survival of hepatocellular carcinoma in a low-incidence country: Data from the Netherlands in the period 2009-2016. Eur J Cancer. 2020;137:214-23.PubMedCrossRef
3.
Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147(2):317-30.PubMedCrossRef
4.
Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol. 2009;20 Suppl 7:vii1-vii6.
5.
Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer G. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10(2 Suppl 1):S115–20.
6.
Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Jr., Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30(4):571-92.PubMedCrossRef
7.
Sangro B, Martinez-Urbistondo D, Bester L, Bilbao JI, Coldwell DM, Flamen P, et al. Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review. Hepatology. 2017;66(3):969-82.PubMedCrossRef
8.
Gabr A, Kallini JR, Gates VL, Hickey R, Kulik L, Desai K, et al. Same-day (90)Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging. 2016;43(13):2353-9.PubMedCrossRef
9.
Gabr A, Ranganathan S, Mouli SK, Riaz A, Gates VL, Kulik L, et al. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. J Hepatol. 2020;72(6):1151-8.PubMedCrossRef
10.
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-50.PubMedCrossRef
11.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
12.
Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79(1):163-71.PubMedCrossRef
13.
Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192-201.PubMedCrossRef
14.
Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology. 2018;287(3):1050-8.PubMedCrossRef
15.
Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2020.
16.
Biederman DM, Titano JJ, Korff RA, Fischman AM, Patel RS, Nowakowski FS, et al. Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma. J Vasc Interv Radiol. 2018;29(1):30–7 e2.
17.
Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, et al. Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study. J Vasc Interv Radiol. 2017;28(6):777–85 e1.
18.
Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.
19.
Gabr A, Polineni P, Mouli SK, Riaz A, Lewandowski RJ, Salem R. Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma. Semin Nucl Med. 2019;49(3):197-203.PubMedCrossRef
20.
Azoulay D, Castaing D, Krissat J, Smail A, Hargreaves GM, Lemoine A, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg. 2000;232(5):665-72.PubMedPubMedCentralCrossRef
21.
Gaba RC, Lewandowski RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16(6):1587-96.PubMedCrossRef
22.
Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, et al. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(3):392-401.PubMedCrossRef
23.
Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, et al. (90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99-105.PubMedCrossRef
24.
Teo JY, Goh BK, Cheah FK, Allen JC, Lo RH, Ng DC, et al. Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radiation therapy with 90Y in patients with hepatocellular carcinoma. J Dig Dis. 2014;15(8):444-50.PubMedCrossRef
25.
Garlipp B, de Baere T, Damm R, Irmscher R, van Buskirk M, Stubs P, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology. 2014;59(5):1864-73.PubMedCrossRef
26.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624-36.PubMedCrossRef
27.
Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018;36(19):1913-21.PubMedCrossRef
28.
Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164-74.PubMedCrossRef
29.
Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, et al. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014;61(2):309-17.PubMedCrossRef
30.
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17-29.PubMedCrossRef
31.
Murray LJ, Dawson LA. Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Semin Radiat Oncol. 2017;27(3):247-55.PubMedCrossRef
32.
Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, et al. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108(9).
33.
Dobrzycka M, Spychalski P, Rostkowska O, Wilczynski M, Kobiela P, Grat M, et al. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol. 2019;58(12):1706-13.PubMedCrossRef
34.
Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, et al. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer. 2020;134:41-51.PubMedPubMedCentralCrossRef
35.
Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, et al. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. Hepatol Res. 2020.
36.
Jang WI, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, et al. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy. Cancer. 2020;126(2):363-72.PubMedCrossRef
37.
Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122(13):2041-9.PubMedCrossRef
38.
Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631-9.CrossRef
39.
Eriguchi T, Takeda A, Oku Y, Ishikura S, Kimura T, Ozawa S, et al. Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma - benchmark for a prospective multi-institutional study. Radiat Oncol. 2013;8:113.PubMedPubMedCentralCrossRef
40.
Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, et al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81-7.PubMedCrossRef
41.
Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2016;34(5):452-9.PubMedCrossRef
42.
Seo YS, Kim MS, Yoo HJ, Jang WI, Paik EK, Han CJ, et al. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis. Cancer Med. 2016;5(11):3094-101.PubMedPubMedCentralCrossRef
43.
Pan YX, Fu YZ, Hu DD, Long Q, Wang JC, Xi M, et al. Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol. 2020;10:1639.
44.
Nabavizadeh N, Jahangiri Y, Rahmani R, Tomozawa Y, Geeratikun Y, Chen Y, et al. Thermal Ablation Versus Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score Weighted Analysis. AJR Am J Roentgenol. 2020.
45.
Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73(1):121–9.
46.
Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92–9.
47.
O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl. 2012;18(8):949-54.PubMedCrossRef
48.
Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016;34(5):460-8.PubMedCrossRef
49.
Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74(3):831-6.PubMedCrossRef
50.
Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, et al. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys. 2019;105(1):64-72.PubMedCrossRef
51.
Kimura K, Nakamura T, Ono T, Azami Y, Suzuki M, Wada H, et al. Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm. Hepatol Res. 2017.
52.
Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, et al. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108(3):497-503.PubMedPubMedCentralCrossRef
53.
Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, et al. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. Int J Radiat Oncol Biol Phys. 2016;95(1):477-82.PubMedCrossRef
54.
Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, et al. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol. 2014;190(9):806-14.PubMedCrossRef
55.
Sebastian NT, Miller ED, Yang X, Diaz DA, Tan Y, Dowell J, et al. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2020.
56.
Hardy-Abeloos C, Lazarev S, Ru M, Kim E, Fischman A, Moshier E, et al. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization. Int J Radiat Oncol Biol Phys. 2019;105(5):968-76.PubMedCrossRef
57.
Jun BG, Kim SG, Kim YD, Cheon GJ, Han KH, Yoo JJ, et al. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for </=5cm hepatocellular carcinoma: Propensity score matching analysis. PLoS One. 2018;13(10):e0206381.PubMedPubMedCentralCrossRef
58.
Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, et al. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer. 2016;16(1):834.PubMedPubMedCentralCrossRef
59.
Paik EK, Kim MS, Jang WI, Seo YS, Cho CK, Yoo HJ, et al. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol. 2016;11:22.PubMedPubMedCentralCrossRef
60.
Jacob R, Turley F, Redden DT, Saddekni S, Aal AK, Keene K, et al. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of >/= 3 cm. HPB (Oxford). 2015;17(2):140-9.PubMedCrossRef
61.
Zhong NB, Lv GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (>/=10 cm) hepatocellular carcinomas: A clinical study. Mol Clin Oncol. 2014;2(5):839-44.PubMedPubMedCentralCrossRef
62.
Cho Y, Kim JW, Kim JK, Lee KS, Lee JI, Lee HW, et al. Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2020;12(6).
63.
Zhao J, Li D, Shi Y, Shi F, Feng C, Li W, et al. Transarterial Infusion Chemotherapy With and Without Embolisation in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. Ann Acad Med Singapore. 2017;46(5):174-84.PubMed
64.
Fujino H, Kimura T, Aikata H, Miyaki D, Kawaoka T, Kan H, et al. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2015;45(6):607-17.PubMedCrossRef
65.
Kouloulias V, Mosa E, Georgakopoulos J, Platoni K, Brountzos I, Zygogianni A, et al. Three-dimensional conformal radiotherapy for hepatocellular carcinoma in patients unfit for resection, ablation, or chemotherapy: a retrospective study. ScientificWorldJournal. 2013;2013:780141.PubMedPubMedCentralCrossRef
66.
Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, et al. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatol Res. 2012;42(5):442-53.PubMedCrossRef
67.
Kodama K, Kawaoka T, Aikata H, Uchikawa S, Nishida Y, Inagaki Y, et al. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. Oncology. 2018;94(4):215-22.PubMedCrossRef
68.
Onishi H, Nouso K, Nakamura S, Katsui K, Wada N, Morimoto Y, et al. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. Hepatol Int. 2015;9(1):105-12.PubMedCrossRef
69.
Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: A meta-analysis and systemic review. Radiother Oncol. 2018;129(1):123-9.PubMedCrossRef
70.
Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, et al. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. J Clin Oncol. 2019;37(24):2141-51.PubMedCrossRef
71.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.PubMedCrossRef
72.
Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol. 2016;65(6):1140-7.PubMedCrossRef
73.
Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R, et al. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. Hepatology. 2017;65(1):122-33.PubMedCrossRef
74.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-73.PubMedCrossRef
75.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66.PubMedCrossRef
76.
Parikh ND, Singal AG, Hutton DW. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. Cancer.n/a-n/a.
77.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54-63.PubMedPubMedCentralCrossRef
78.
Zhu AX, Galle PR, Kudo M, Finn RS, Qin S, Xu Y, et al. A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2). J Clin Oncol. 2018;36(4_suppl):TPS538-TPS.
79.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492-502.PubMedPubMedCentralCrossRef
80.
Yau T, Park J, Finn R, Cheng A-L, Mathurin P, Edeline J, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Annals of Oncology. 2019;30:v874-v5.CrossRef
81.
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193-202.PubMed
82.
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020.
83.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New England Journal of Medicine. 2020;382(20):1894-905.CrossRef
84.
Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(8):565-75.PubMedCrossRef
85.
Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. Journal of hepatology. 2016;64(5):1090-8.PubMedCrossRef
Metadata
Title
Frontiers of therapy for hepatocellular carcinoma
Authors
Michael Heller
Neehar D. Parikh
Nicholas Fidelman
Dawn Owen
Publication date
01-08-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 8/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-021-03065-0

Other articles of this Issue 8/2021

Abdominal Radiology 8/2021 Go to the issue

Hepatobiliary

Comparison of unenhanced and contrast-enhanced 3 T magnetic resonance portovenography in children with extra hepatic portal venous obstruction

Hepatobiliary

Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features

Special Section: HCC Treatment

Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation—part one: curative intention

Special Section: HCC Treatment

Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma

Interventional Radiology

Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis

Special Section: HCC Treatment

Artificial intelligence in assessment of hepatocellular carcinoma treatment response

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits